Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer

被引：32

作者：

Kunikane H. ^{[1
]}

Watanabe K. ^{[1
]}

Fukuoka M. ^{[2
]}

Saijo N. ^{[3
]}

Furuse K. ^{[4
]}

Ikegami H. ^{[5
]}

Ariyoshi Y. ^{[6
]}

Kishimoto S. ^{[7
]}

机构：

[1] Department of Respiratory Medicine, Yokohama Municipal Citizen's Hospital, Hodogaya-ku, Yokohama 240-8555

[2] Fourth Department of Internal Medicine, Kinki University, School of Medicine, Osaka-sayama

[3] Department of Medical Oncology and Radiation Oncology, National Cancer Center Central Hospital, Tokyo

[4] Department of Internal Medicine, National Kinki Central Hospital for Chest Diseases, Sakai

[5] Department of Internal Medicine, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka

[6] Department of Internal Medicine, Aichi Prefectural Hospital, Okazaki

[7] Osaka Prefectural Habikino Hospital, Habikino

来源：

International Journal of Clinical Oncology | 2001年 / 6卷 / 6期

关键词：

Anemia; Chemotherapy; Erythropoietin; Non-small cell lung cancer; Randomized control trial;

D O I：

10.1007/s10147-001-8031-y

中图分类号：

学科分类号：

摘要：

Background. We studied the clinical effect of recombinant human erythropoietin (r-huEPO) on anemia induced by two courses of cisplatin-based chemotherapy in patients with non-small cell lung cancer (NSCLC). Methods. Seventy-two patients with NSCLC were randomized into three groups, receiving 100, or 200 IU/kg of r-huEPO, or placebo. The r-huEPO and placebo were administered subcutaneously three times a week for 6 weeks, starting 2 weeks after the initiation of chemotherapy. Results. In the 53 evaluable patients, hemoglobin (Hb) levels at the nadir after the second cycle of chemotherapy were significantly elevated compared with the nadir after the first cycle in both r-huEPO treated groups, while this level was decreased in the placebo group. Hb levels at the end of the second course of chemotherapy (week 8) in both r-huEPO groups were higher than that in the placebo groups. No adverse drug reaction attributable to r-huEPO was observed. Serum erythropoietin levels after the administration of r-huEPO were higher than those after placebo administration. Conclusions. r-huEPO had an effect in preventing anemia in patients with NSCLC who had cisplatin-based chemotherapy.

引用

页码：296 / 301

页数：5

共 24 条

[11]

Eschbach J.W., Kelly M.R., Haley R., Et al., Treatment of the anemia of progressive renal failure with recombinant human erythropoietin, N Engl J Med, 321, pp. 158-163, (1989)

[12]

Ludwig H., Fritz E., Kotzmann H., Et al., Erythropoietin treatment in anemia associated with multiple myeloma, N Engl J Med, 322, pp. 1693-1699, (1990)

[13]

Sasaki H., Bothner B., Dell A., Fukuda M., Calbohydrate structure of erythropoietin expressed in Chinese hamster overy cells by a human erythropoietin cDNA, J Biol Chem, 262, pp. 12059-12076, (1987)

[14]

Recny M.A., Scoble H.A., Kim Y., Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin. Identification of des-arginine 166 erythropoietin, J Biol Chem, 262, pp. 17156-17163, (1987)

[15]

WHO handbook for reporting results of cancer treatment, (1979)

[16]

Muirhead N., Bargmann J., Burgess E., Et al., Evidence-based recommendations for the clinical use of recombinant human erythropoietin, Am J Kidney Dis, 26, pp. 1-24, (1995)

[17]

Campas E., Radford J., Steward W., Et al., Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer, J Clin Oncol, 13, pp. 1623-1631, (1995)

[18]

Mastro L.D., Venturini M., Lionetto R., Et al., Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia, J Clin Oncol, 15, pp. 2715-2721, (1997)

[19]

Oberhoff C., Neri B., Amadori D., Et al., Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: A randomized, controlled study, Ann Oncol, 9, pp. 255-260, (1998)

[20]

Dunphy F.R., Harrison B.R., Dunleavy T.L., Et al., Erythropoietin reduces anemia and transfusions: A randomized trial with or without erythropoietin during chemotherapy, Cancer, 86, pp. 1362-1367, (1999)

← 1 2 3 →